HeraMED Ltd. (AU:HMD) has released an update.
HeraMED Limited acknowledges the late lodgment of Appendix 3Y due to administrative oversight amid corporate restructuring and management changes, including the appointment of a new CEO. The oversight occurred during the company’s rights issue, in which Director David Hinton received shares, and has since been corrected with the aid of Bio101, a professional services firm ensuring future compliance. HeraMED is confident in meeting ASX Listing Rules going forward.
For further insights into AU:HMD stock, check out TipRanks’ Stock Analysis page.
